Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.

It is widely accepted that most cell types efficiently exclude oligonucleotides in vitro and require specific delivery systems, such as cationic lipids, to enhance uptake and subsequent antisense effects. Oligonucleotides are not readily transfected into leukaemia cell lines using cationic lipid systems and streptolysin O (SLO) is used to effect their delivery. We wished to investigate the optimal oligonucleotide composition for antisense efficacy and specificity following delivery into leukaemia cells using SLO. For this study the well characterised chronic myeloid leukaemia cell line KYO-1 was selected and oligonucleotides (20mers) were targeted to an empirically identified accessible site of c- myc mRNA. The efficiency and specificity of antisense effect was measured 4 and 24 h after SLO-mediated delivery of the oligonucleotides. C5-propyne phosphodiester and phosphorothioate compounds were found to present substantial non-specific effects at 20 microM but were inactive at 0.2 microM. Indeed, no antisense-specific effect was noted at any concentration at either time. All of the other oligonucleotides tested induced some measurable antisense effect, except 7 (chimeric, all-phosphorothioate, 2'-methoxyethoxy termini) which was essentially inactive at 20 microM. The rank efficiency order of the remaining antisense compounds was 4 = 3 >> 9 >> 10 = 8 = 5 = 6 > 11. The efficient antisense effects induced by the chimeric methylphosphonate-phosphodiester compounds were found to be highly specific. Increased phosphorothioate content in the oligonucleotide backbone correlated with reduced antisense activity (efficacy: 2'-methoxyethoxy series 9 >> 8 >> 7, 2'-methoxytriethoxy series 10 > 11). No consistent evidence was obtained for increased activity correlating with increased oligonucleotide-mRNA heteroduplex thermal stability. In conclusion, the chimeric methylphosphonate-phosphodiester oligodeoxynucleotides present the most favourable characteristics of the compounds tested, for efficient and specific antisense suppression of gene expression following SLO-mediated delivery.

[1]  D. Spiller,et al.  Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. , 1993, Anti-cancer drug design.

[2]  L. Neckers,et al.  Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. , 1993, Nucleic acids research.

[3]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[4]  B Calabretta,et al.  Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. , 1994, Leukemia.

[5]  R. Hanecak,et al.  Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes , 1996, Journal of virology.

[6]  D. Spiller,et al.  Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. , 1995, Antisense research and development.

[7]  T. Smetsers,et al.  Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. , 1995, Leukemia.

[8]  P. D. Cook,et al.  Oligodeoxynucleotides containing 2'-O-modified adenosine: synthesis and effects on stability of DNA:RNA duplexes. , 1993, Biochemistry.

[9]  T. Papayannopoulou,et al.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.

[10]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[11]  D. Spiller,et al.  Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. , 1995, Nucleic acids research.

[12]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Agrawal,et al.  Oligodeoxynucleoside methylphosphonates: synthesis and enzymic degradation , 1987 .

[14]  B. Froehler,et al.  Potent and selective inhibition of gene expression by an antisense heptanucleotide , 1996, Nature Biotechnology.

[15]  P. D. Cook,et al.  Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines. , 1993, Nucleic acids research.

[16]  D. Spiller,et al.  Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. , 1995, Antisense research and development.

[17]  K. Shinozuka,et al.  Physicochemical properties of phosphorothioate oligodeoxynucleotides. , 1988, Nucleic acids research.

[18]  C. Kessler,et al.  Non-radioactive labeling of RNA transcripts in vitro with the hapten digoxigenin (DIG); hybridization and ELISA-based detection. , 1990, Nucleic acids research.

[19]  I. Sánchez-García,et al.  Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[21]  C. Sawyers,et al.  Dominant negative MYC blocks transformation by ABL oncogenes , 1992, Cell.

[22]  R. V. Giles,et al.  Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. , 1992, Nucleic acids research.

[23]  S. Agrawal.  Protocols for oligonucleotides and analogs : synthesis and properties , 1993 .

[24]  S. Dhut,et al.  BCR-ABL and BCR proteins: biochemical characterization and localization. , 1990, Leukemia.

[25]  B. Calabretta,et al.  Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. , 1991, Science.

[26]  S. Agrawal.  Protocols for Oligonucleotides and Analogs , 1993 .

[27]  Pierre Martin,et al.  Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren Oligonucleotide , 1995 .

[28]  L. Neckers,et al.  Characterization of oligonucleotide transport into living cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Nestle,et al.  Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. , 1994, The Journal of investigative dermatology.

[30]  Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. , 1993, Anti-cancer drug design.

[31]  C. Sawyers,et al.  Differential complementation of Bcr-Abl point mutants with c-Myc. , 1994, Science.

[32]  R. V. Giles,et al.  Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides. , 1992, Anti-cancer drug design.

[33]  R. Clark,et al.  Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients , 1997, Leukemia.

[34]  Bonny Bryan,et al.  Nucleic Acids Research Nucleic Acids Research , 2022 .

[35]  J. Melo,et al.  Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. , 1994, Leukemia.

[36]  P. D. Cook,et al.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. , 1995, Nucleic acids research.

[37]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[38]  D. Fabbro,et al.  Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. , 1996, Biochemical Society transactions.

[39]  Teri,et al.  Molecular Cloning A Laboratory Manual Second Edition Sambrook , 1989 .

[40]  E. Lesnik,et al.  2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[41]  D. Spiller,et al.  Enhanced Antisense Effects Resulting from an Improved Streptolysin-O Protocol for Oligodeoxynucleotide Delivery into Human Leukaemia Cells , 1997 .

[42]  A. Periasamy,et al.  Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. , 1991, Nucleic acids research.

[43]  M. Blumenfeld,et al.  BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. , 1995, Blood.

[44]  B. Monia,et al.  Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras* , 1996, The Journal of Biological Chemistry.

[45]  C. Hunt,et al.  Characteristics of oligonucleotide uptake in human keratinocyte cultures. , 1993, The Journal of investigative dermatology.

[46]  B. Froehler,et al.  Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. , 1995, Biochemistry.

[47]  R. Griffey,et al.  Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. , 1995, The Biochemical journal.

[48]  C. Bennett,et al.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. , 1992, Molecular pharmacology.

[49]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[50]  F. Young.  Biochemistry , 1955, The Indian Medical Gazette.

[51]  B. Froehler,et al.  Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. , 1993, Science.

[52]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[53]  D. Spiller,et al.  The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. , 1992, Anti-cancer drug design.

[54]  K. Moelling,et al.  Isolation and characterization of the human cellular myc gene product. , 1985, Biochemistry.

[55]  C. Stein.  Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. , 1996, Trends in biotechnology.

[56]  D. Spiller,et al.  Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. , 1995, Blood.